Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Werewolf Therapeutics, Inc.

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate in the BIO International Convention
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
From Werewolf Therapeutics, Inc.
Via GlobeNewswire
Tickers HOWL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.